Tibolone Tablets contain Tibolone.<\/p>\n
The tablets comply with the requirements stated under Tablets and with the following requirements.<\/p>\n
Content of tibolone, C21<\/sub>H28<\/sub>O2<\/sub><\/strong><\/p>\n 90.0 to 105.0% of the stated amount.<\/p>\n A. Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions.<\/p>\n (1) Shake a quantity of the powdered tablets containing 5 mg of Tibolone with 5 mL of acetonitrile, centrifuge and use the supernatant liquid.<\/p>\n (2) 0.1% w\/v of tibolone BPCRS in acetonitrile.<\/p>\n (a) Use as the coating silica gel G (Merck silica gel 60 plates are suitable).<\/p>\n (b) Use the mobile phase described below.<\/p>\n (c) Apply 4 \u03bcL of each solution.<\/p>\n (d) Develop the plate to 15 cm.<\/p>\n (e) After removal of the plate dry in air, spray with ethanolic sulfuric acid (2%) and heat at 100\u00b0 to 105\u00b0 for 3 minutes.<\/p>\n Allow to cool and examine under ultraviolet light (366 nm) and in daylight.<\/p>\n 5 volumes of acetone and 95 volumes of dichloromethane.<\/p>\n The principal spot in the chromatogram obtained with solution (1) is similar in position, colour and size to that in the chromatogram obtained with solution (2).<\/p>\n B. In the test for Uniformity of content, the chromatogram obtained with solution (1) exhibits a peak with the same retention time as the peak due to tibolone in the chromatogram obtained with solution (2).<\/p>\n Comply with the requirements in the dissolution test for tablets and capsules, Appendix XII B1.<\/p>\n (a) Use Apparatus 2, rotating the paddle at 50 revolutions per minute.<\/span><\/p>\n (b) Use 500 mL of a 0.25% w\/v solution of sodium lauryl sulfate, at a temperature of 37\u00b0, as the medium.<\/span><\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions.<\/span><\/p>\n (1) After 45 minutes withdraw a sample of the medium and filter. Use the filtered medium, diluted with a 0.25% w\/v <\/span>solution of sodium lauryl sulfate to produce a solution expected to contain about 0.0005% w\/v of Tibolone.<\/span><\/p>\n (2) 0.0005% w\/v of tibolone BPCRS in a mixture of 1 volume of methanol and 99 volumes of a 0.25% w\/v solution of <\/span>sodium lauryl sulfate.<\/span><\/p>\n (a) Use a stainless steel column (10 cm \u00d7 4.6 mm) packed with octadecylsilyl silica gel for chromatography (5 \u03bcm) (Hypersil ODS is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 0.5 mL per minute.<\/p>\n (d) Use a column temperature of 40\u00b0.<\/p>\n (e) Use a detection wavelength of 205 nm.<\/p>\n (f) Inject 200 \u03bcL of each solution.<\/p>\n 23 volumes of water and 77 volumes of methanol R2.<\/p>\n Calculate the total content of tibolone, C21H28O2, in the medium from the chromatograms obtained and using the declared <\/span>content of C21H28O2 <\/span>in tibolone BPCRS.<\/span><\/p>\n The amount of tibolone released is not less than 75% (Q) of the stated amount.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions in absolute ethanol.<\/p>\n (1) To a quantity of the powdered tablets containing 25 mg of Tibolone add 40 mL of absolute ethanol, mix with the aid of ultrasound, add sufficient absolute ethanol to produce 50 mL, centrifuge and use the supernatant.<\/p>\n (2) 0.05% w\/v of tibolone impurity standard BPCRS (containing impurity B, impurity C and 1% w\/w of impurity A).<\/p>\n (3) Dilute 1 volume of solution (2) to 10 volumes.<\/p>\n (a) Use a stainless steel column (15 cm \u00d7 3.9 mm) packed with octadecylsilyl silica gel for chromatography (4 \u03bcm) (Waters Nova-Pak C18 is suitable).<\/p>\n (b) Use isocratic elution and the mobile phase described below.<\/p>\n (c) Use a flow rate of 1 mL per minute.<\/p>\n (d) Use a column temperature of 40\u00b0.<\/p>\n (e) Use a detection wavelength of 240 nm.<\/p>\n (f) Inject 10 \u03bcL of each solution.<\/p>\n 28 volumes of tetrahydrofuran and 72 volumes of water.<\/p>\n The test is not valid unless:<\/p>\n the chromatogram obtained with solution (2) closely resembles the chromatogram supplied with tibolone impurity standard BPCRS;<\/p>\n in the chromatogram obtained with solution (2), the resolution between the peaks due to impurity A and impurity B is at least 2.0;<\/p>\n in the chromatogram obtained with solution (3), the signal-to-noise ratio of the peak due to impurity A is at least 10.<\/p>\n Identify any peak in the chromatogram obtained with solution (1) corresponding to impurity C using the chromatogram obtained with solution (2) and multiply the area of this peak by the following correction factor: 0.79.<\/p>\n In the chromatogram obtained with solution (1):<\/p>\n the area of any peak corresponding to impurity A is not greater than the area of the corresponding peak in the chromatogram obtained with solution (2) (1%);<\/p>\n the area of any peak corresponding to impurity B is not greater than the area of the peak due to impurity A in the chromatogram obtained with solution (2) (1%);<\/p>\n the area of any peak corresponding to impurity C is not greater than 5 times the area of the peak due to impurity A in the chromatogram obtained with solution (2) (5%);<\/p>\n the area of any other secondary peak is not greater than 0.5 times the area of the peak due to impurity A in the chromatogram obtained with solution (2) (0.5%);<\/p>\n the sum of the areas of all the secondary peaks is not greater than 6.5 times the area of the peak due to impurity A in the chromatogram obtained with solution (2) (6.5%).<\/p>\n Disregard any peak with an area less than the area of the peak due to impurity A in the chromatogram obtained with solution (3) (0.1%).<\/p>\n For tablets containing 2 mg or less or 2% w\/w or less of tibolone<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions in absolute ethanol.<\/p>\n (1) Finely crush one tablet, moisten the powdered tablet with sufficient absolute ethanol to produce a solution containing 0.05% w\/v of Tibolone, disperse with the aid of ultrasound for 10 minutes and centrifuge.<\/p>\n (2) 0.05% w\/v of tibolone BPCRS.<\/p>\n (3) 0.05% w\/v of tibolone impurity standard BPCRS.<\/p>\n The chromatographic procedure described under Related substances may be used with a detection wavelength of 210 nm.<\/p>\n The test is not valid unless: the chromatogram obtained with solution (3) closely resembles the chromatogram supplied with tibolone impurity standard BPCRS; in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity A and impurity B is at least 2.0.<\/p>\n Calculate the content of C21<\/sub>H28<\/sub>O2<\/sub> in each tablet using the declared content of C21<\/sub>H28<\/sub>O2<\/sub> in tibolone BPCRS.<\/p>\n Use the average of the individual results determined in the test for Uniformity of content.<\/p>\n Carry out the method for liquid chromatography, Appendix III D, using the following solutions in absolute ethanol.<\/p>\n (1) To a quantity of the powdered tablets containing 25 mg of Tibolone add 40 mL of absolute ethanol, mix with the aid of ultrasound, add sufficient absolute ethanol to produce 50 mL and centrifuge.<\/p>\n (2) 0.05% w\/v of tibolone BPCRS.<\/p>\n (3) 0.05% w\/v of tibolone impurity standard BPCRS.<\/p>\n The chromatographic procedure described under Related substances may be used with a detection wavelength of 210 nm.<\/p>\n The test is not valid unless:<\/p>\n the chromatogram obtained with solution (3) closely resembles the chromatogram supplied with tibolone impurity standard BPCRS; in the chromatogram obtained with solution (3), the resolution between the peaks due to impurity A and impurity B is at least 2.0.<\/p>\n Calculate the content of C21<\/sub>H28<\/sub>O2<\/sub> in the tablets using the declared content of C21<\/sub>H28<\/sub>O2<\/sub> in tibolone BPCRS.<\/p>\n A. 10,17-dihydroxy-7\u03b1-methyl-19-nor-10\u03be,17\u03b1-pregn-4-en-20-yn-3-one (European Pharmacopoeia impurity A),<\/p>\n B. 10-hydroperoxy-17-hydroxy-7\u03b1-methyl-19-nor-10\u03be,17\u03b1-pregn-4-en-20-yn-3-one (European Pharmacopoeia impurity B),<\/p>\n C. 17-hydroxy-7\u03b1-methyl-19-nor-10\u03be,17\u03b1-pregn-4-en-20-yn-3-one (European Pharmacopoeia impurity C).<\/p>\n","protected":false},"excerpt":{"rendered":" DEFINITION Tibolone Tablets contain Tibolone. The tablets comply with the requirements stated under Tablets and with the following requirements. Content of tibolone, C21H28O2 90.0 to 105.0% of the stated amount. IDENTIFICATION A. Carry out the method for thin-layer chromatography, Appendix III A, using the following solutions. (1) Shake a quantity of the powdered tablets containing…<\/p>\n","protected":false},"author":4,"featured_media":21371,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[175],"tags":[],"class_list":["post-21369","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-formulated-preparations-specific-monographs"],"acf":[],"_links":{"self":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/21369","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/comments?post=21369"}],"version-history":[{"count":2,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/21369\/revisions"}],"predecessor-version":[{"id":21373,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/posts\/21369\/revisions\/21373"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media\/21371"}],"wp:attachment":[{"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/media?parent=21369"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/categories?post=21369"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nhathuocngocanh.com\/bp\/wp-json\/wp\/v2\/tags?post=21369"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}IDENTIFICATION<\/h2>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
MOBILE PHASE<\/h4>\n
CONFIRMATION<\/h4>\n
TESTS<\/h2>\n
Dissolution<\/h3>\n
TEST CONDITIONS<\/span><\/h4>\n
PROCEDURE<\/span><\/h4>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
MOBILE PHASE<\/h4>\n
DETERMINATION OF CONTENT<\/h4>\n
LIMITS<\/h4>\n
Related substances<\/h3>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
MOBILE PHASE<\/h4>\n
SYSTEM SUITABILITY<\/h4>\n
LIMITS<\/h4>\n
Uniformity of content<\/h3>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
SYSTEM SUITABILITY<\/h4>\n
DETERMINATION OF CONTENT<\/h4>\n
ASSAY<\/h2>\n
For tablets containing 2 mg or less or 2% w\/w or less of tibolone<\/h3>\n
For tablets containing more than 2 mg and more than 2% w\/w of tibolone<\/h3>\n
CHROMATOGRAPHIC CONDITIONS<\/h4>\n
SYSTEM SUITABILITY<\/h4>\n
DETERMINATION OF CONTENT<\/h4>\n
IMPURITIES<\/h2>\n